Shufro Rose & Co’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Shufro Rose & Co’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,941	Closed	-$9.32K	–	355
2022 Q4	$9.32K	Hold	12,941	–	–	﹤0.01%	341
2022 Q3	$16K	Hold	12,941	–	–	﹤0.01%	332
2022 Q2	$15K	Hold	12,941	–	–	﹤0.01%	318
2022 Q1	$28K	Hold	12,941	–	–	﹤0.01%	331
2021 Q4	$19K	Hold	12,941	–	–	﹤0.01%	311
2021 Q3	$38K	Hold	12,941	–	–	﹤0.01%	296
2021 Q2	$43K	Hold	12,941	–	–	﹤0.01%	298
2021 Q1	$49K	Hold	12,941	–	–	﹤0.01%	300
2020 Q4	$46K	Hold	12,941	–	–	﹤0.01%	284
2020 Q3	$85K	Hold	12,941	–	–	0.01%	266
2020 Q2	$96K	Hold	12,941	–	–	0.01%	267
2020 Q1	$61K	Sell	12,941 -1	-0%	-$11	0.01%	276
2019 Q4	$167K	Hold	12,942	–	–	0.02%	282
2019 Q3	$136K	Hold	12,942	–	–	0.01%	289
2019 Q2	$220K	Hold	12,942	–	–	0.02%	258
2019 Q1	$436K	Buy	+12,942	New	+$433K	0.04%	171

Other funds holding BLCM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Shufro Rose & Co's BLCM Position: Q1 2023 in Review

Shufro Rose & Co sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2023, closing a stake of 12,941 shares — an estimated $9.32K sold.

Shufro Rose & Co first reported a position in BLCM in Q1 2019 and held it in 16 quarters. The position peaked at $436K in Q1 2019. 25 funds tracked by Wall St. Rank hold BLCM as of Q1 2023.

Shufro Rose & Co reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Shufro Rose & Co sold 12,941 Bellicum Pharmaceuticals, Inc. shares in Q1 2023, an estimated $9.32K.
Shufro Rose & Co first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2019 and held it in 16 quarters.
Shufro Rose & Co's Bellicum Pharmaceuticals, Inc. position peaked at $436K in Q1 2019.
25 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2023.

Based on Shufro Rose & Co's 13F filing for Q1 2023, filed 20 Apr 2023.